Wednesday, June 10, 2026

Patent directory · USPTO A61K / A61P

Browse patents

Browse 30,257 pharma-relevant patents (US A61K/A61P) linked to tracked companies, drugs, and pipeline programs.

Patents indexed 30,257
Companies 1,769
Drugs linked 4,797

Quick answer

NovaPharmaNews indexes 30,257 US pharmaceutical patents from USPTO PatentsView (CPC A61K/A61P), cross-linked to company assignees, drug INN profiles, and pipeline programs. Search by patent number, applicant, title, or CPC code — or use facet hubs for expiring patents, assignees, and therapeutic areas.

Patent results

Page 18 of 1,261
  1. US 12396924

    Adapter for use in a planetary mixer

    MEDISCA PHARMACEUTIQUE INC. · Granted Aug 26, 2025 · Expires Aug 21, 2045

    granted
  2. US 12398375

    Methods for improved poxvirus yields

    ARIZONA BOARD OF REGENTS FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY · Granted Aug 26, 2025 · Expires Aug 21, 2045

    granted
  3. US 12397058

    Metabolically stable prodrugs

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Aug 26, 2025 · Expires Aug 21, 2045

    granted
  4. US 12398373

    Enhanced immune effector cells and use thereof

    Fate Therapeutics, Inc. · Granted Aug 26, 2025 · Expires Aug 21, 2045

    granted
  5. US 12398212

    Methods for treating or preventing asthma by administering an IL-4R antagonist

    REGENERON PHARMACEUTICALS, INC. · Granted Aug 26, 2025 · Expires Aug 21, 2045

    granted
  6. US 12397013

    Extrahepatic delivery

    Alnylam Pharmaceuticals, Inc. · Granted Aug 26, 2025 · Expires Aug 21, 2045

    granted
  7. US 12398123

    Chemical inhibition of the E3 ligase subunit FBXO7 confers neuroprotection and anti-inflammatory activity by stabilizing mitochondria

    United States Government as represented by the Department of Veterans Affairs · Granted Aug 26, 2025 · Expires Aug 21, 2045

    granted
  8. US 12398194

    Cell lexpressing two chimeric antigen receptors (CARs) at the cell surface

    AUTOLUS LIMITED · Granted Aug 26, 2025 · Expires Aug 21, 2045

    granted
  9. US 12398178

    Collections of peptides, peptide agents, and methods of use thereof

    Parabilis Medicines, Inc. · Granted Aug 26, 2025 · Expires Aug 21, 2045

    granted
  10. US 12398379

    Compositions and methods for treating ornithine transcarbamylase deficiency

    ARCTURUS THERAPEUTICS, INC. · Granted Aug 26, 2025 · Expires Aug 21, 2045

    granted
  11. US 12397066

    Delivery of gene therapy treatments

    United States Government as represented by the Department of Veterans Affairs · Granted Aug 26, 2025 · Expires Aug 21, 2045

    granted
  12. US 12398197

    Antibodies with engineered CH2 domains, compositions thereof and methods of using the same

    Sutro Biopharma, Inc. · Granted Aug 26, 2025 · Expires Aug 21, 2045

    granted
  13. US 12398179

    Nanomolar peptides and derivatives to differentially modulate ephrin receptors

    SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · Granted Aug 26, 2025 · Expires Aug 21, 2045

    granted
  14. US 12397062

    Muscle targeting complexes and uses thereof for treating dystrophinopathies

    Dyne Therapeutics, Inc. · Granted Aug 26, 2025 · Expires Aug 21, 2045

    granted
  15. US 12398154

    Azaquinazoline pan-KRas inhibitors

    Mirati Therapeutics, Inc. · Granted Aug 26, 2025 · Expires Aug 21, 2045

    granted
  16. US 12398140

    Substituted pyrrolo [2,3-d]pyrimidines for treating familial dysautonomia

    PTC THERAPEUTICS, INC. · Granted Aug 26, 2025 · Expires Aug 21, 2045

    granted
  17. WO 2025172541

    NOUVELLE COMPOSITION POUR L'AMÉLIORATION DE LA RECONSTITUTION DE LA MOELLE OSSEUSE ET DE LA RÉCUPÉRATION PÉRIPHÉRIQUE DES NUMÉRATIONS DE NEUTROPHILES ET DE PLAQUETTES

    AOP ORPHAN PHARMACEUTICALS GMBH [AT] · Granted Aug 21, 2025 · Expires Aug 16, 2045

    granted
  18. WO 2025172818

    POLYTHÉRAPIE À BASE DE PYRILUTAMIDE

    CASSIOPEA S P A [IT] · Granted Aug 21, 2025 · Expires Aug 16, 2045

    granted
  19. AR 133055

    DOMINIOS VARIABLES ÚNICOS DE INMUNOGLOBULINA DIRIGIDOS A PD-L1

    ABLYNX NV [BE] · Granted Aug 20, 2025 · Expires Aug 15, 2045

    granted
  20. AR 133027

    COMPOSICIÓN FARMACÉUTICA QUE COMPRENDE UN COMPUESTO DE QUINAZOLINA

    ASTELLAS PHARMA INC [JP] · Granted Aug 20, 2025 · Expires Aug 15, 2045

    granted
  21. US 12390453

    Method for reducing side effects from administration of phosphodiesterase-4 inhibitors

    ARCUTIS BIOTHERAPEUTICS, INC. · Granted Aug 19, 2025 · Expires Aug 14, 2045

    granted
  22. US 12391760

    Method of treating primary sclerosing cholangitis

    Takeda Pharmaceutical Company Limited · Granted Aug 19, 2025 · Expires Aug 14, 2045

    granted
  23. US 12391765

    Methods and materials for assessing response to plasmablast- and plasma cell-depleting therapies

    Takeda Pharmaceutical Company Limited · Granted Aug 19, 2025 · Expires Aug 14, 2045

    granted
  24. US 12391920

    Models of tauopathy

    REGENERON PHARMACEUTICALS, INC. · Granted Aug 19, 2025 · Expires Aug 14, 2045

    granted

Frequently asked questions

What patents are included in this directory?

We index 30,257 published US pharma-relevant patents filtered to CPC classes A61K and A61P, with assignee links to our company directory where a match exists.

How do I search for a patent?

Use the search box to match patent number, title, applicant name, or CPC classification (e.g. A61K). For cross-entity queries spanning news and drugs, use the global search.

How is this different from the patent intelligence dashboard?

The dashboard at /patents highlights expirations, recent grants, and assignee rankings. Browse is the full paginated directory with search — best for looking up a specific filing or applicant portfolio slice.